Q1 Earnings Forecast for NMRA Issued By HC Wainwright

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Neumora Therapeutics in a research report issued on Monday, December 16th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.46) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS and Q4 2025 earnings at ($0.44) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the firm posted ($1.14) earnings per share.

Several other research firms have also recently weighed in on NMRA. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Neumora Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $23.40.

Neumora Therapeutics Stock Up 3.1 %

NASDAQ:NMRA opened at $10.50 on Wednesday. The stock has a market cap of $1.70 billion, a P/E ratio of -5.61 and a beta of 3.34. The business’s 50-day moving average price is $11.70 and its two-hundred day moving average price is $11.52. Neumora Therapeutics has a twelve month low of $8.33 and a twelve month high of $21.00.

Hedge Funds Weigh In On Neumora Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in Neumora Therapeutics during the 2nd quarter valued at about $566,000. Bank of New York Mellon Corp raised its holdings in shares of Neumora Therapeutics by 474.1% during the second quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company’s stock valued at $2,316,000 after acquiring an additional 194,559 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Neumora Therapeutics in the second quarter worth $166,000. Rhumbline Advisers boosted its holdings in Neumora Therapeutics by 488.3% in the second quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock valued at $1,015,000 after acquiring an additional 85,706 shares in the last quarter. Finally, TD Asset Management Inc increased its position in Neumora Therapeutics by 31.6% during the 2nd quarter. TD Asset Management Inc now owns 144,994 shares of the company’s stock valued at $1,425,000 after purchasing an additional 34,800 shares during the period. 47.65% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Robert A. Lenz sold 5,563 shares of the company’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now directly owns 322,966 shares in the company, valued at $4,847,719.66. This represents a 1.69 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Matthew K. Fust sold 14,049 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares in the company, valued at approximately $342,303. This trade represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. Insiders own 26.40% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.